Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Myriad Genetics, Inc.    MYGN

Delayed Quote. Delayed  - 05/27 09:59:59 pm
34.09 USD   +1.97%
05/20 MYRIAD GENETICS : Statement on HIPAA Complaint from Four Patients
05/19 MYRIAD GENETICS : Statement on HIPAA Complaint from Four Patients
05/19 Myriad Genetics’ Statement on HIPAA Complaint from Four Pat..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies 

Myriad Genetics, Inc. : Near a solid support area

share with twitter share with LinkedIn share with facebook
share via e-mail
02/19/2013 | 03:00pm
Opinion : Bullish above USD 24.2
Target price : USD 26.1
Stop loss: USD 23.6
NASDAQ
Advanced Medical Equipment & Technology

Myriad Genetics' share price was heavily penalized and is now in an oversold situation near to a solid support area.

Myriad Genetics is technically oversold and is near to the USD 24.2 support. This situation gives credit to a potential technical rebound. Thus, the stock could find new energy and would rise towards the next USD 26.1 resistance.

So as to make the most of a potential technical rebound of Myriad Genetics, it seems opportune to take a long position at the current price. A confirmation of this pattern would enable the security to reach the USD 27.62 resistance, with a potential gain of 13.2 %. Investors should not insist under USD 24.19 and place a stop loss order under this threshold.

Myriad Genetics, Inc. : Myriad Genetics, Inc. : Near a solid support area

© Zonebourse.com 2013



share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 2 350 M$ -
Entreprise Value (EV) 2 237 M$ 2 207 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS) 21,5x 19,3x
Capitalization / Revenue 3,11x 2,96x
EV / Revenue 2,96x 2,78x
EV / EBITDA 10,8x 9,86x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,07x 2,84x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 21,3% 23,0%
operating Leverage (Delta EBIT / Delta Sales) - 2,60x
Net Margin (Net Profit / Revenue) 15,1% 15,4%
ROA (Net Profit / Asset) 15,3% 14,8%
ROE (Net Profit / Equities) 16,2% 15,4%
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   1,33% 1,68%
Cash Flow / Sales 21,4% 21,3%
Capital Intensity (Assets / Sales) 0,99x 1,04x
Financial Leverage (Net Debt / EBITDA) -0,55x -0,64x
Income Statement Evolution
More Financials
EPS Revisions